Small interfering RNA-mediated silencing of nicotinamide phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) induce growth inhibition and apoptosis in human multiple myeloma cells: A preliminary study

Ivyna Pau Ni Bong1,2, Ching Ching Ng2*, Shaik Kamal Fakiruddin1, Moon Nian Lim1, Zubaidah Zakaria1

1 Haematology Unit, Cancer Research Centre, Institute for Medical Research, Kuala Lumpur, Malaysia, 2 Department of Genetics and Molecular Biology, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia

ABSTRACT

Multiple myeloma (MM) is a malignancy of B lymphocytes or plasma cells. Our array-based comparative genomic hybridization findings revealed chromosomal gains at 7q22.3 and 1q42.3, where nicotinamide (NAM) phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) genes are localized, respectively. This led us to further study the functions of these genes in myeloma cells. NAMPT is a key enzyme involved in nicotinamide adenine dinucleotide salvage pathway, and it is frequently overexpressed in human cancers. In contrast, little is known about the function of LYST in cancer. The expression of LYST is shown to affect lysosomal size, granule size, and autophagy in human cells. In this study, the effects of small interfering RNA (siRNA)-mediated silencing of NAMPT and LYST on cell proliferation and apoptosis were evaluated in RPMI 8226 myeloma cells. Transfection efficiencies were determined by quantitative real time reverse transcriptase PCR. Cell proliferation was determined using MTT assay, while apoptosis was analyzed with flow cytometry using Annexin V-fluorescein isothiocyanate/propidium iodide assay. The NAMPT protein expression in siRNA-treated cells was estimated by enzyme-linked immunosorbent assay. Our results showed that NAMPT and LYST were successfully knockdown by siRNA transfection (p < 0.05). NAMPT or LYST gene silencing significantly inhibited cell proliferation and induced apoptosis in RPMI 8226 cells (p < 0.05). Silencing of NAMPT gene also decreased NAMPT protein levels (p < 0.01). Our study demonstrated that NAMPT and LYST play pivotal roles in the molecular pathogenesis of MM. This is the first report describing the possible functions of LYST in myelogenesis and its potential role as a therapeutic target in MM.

KEY WORDS: Multiple myeloma; nicotinamide phosphoribosyltransferase; lysosomal trafficking regulator; small interfering RNA; cell proliferation; apoptosis

DOI: http://dx.doi.org/10.17305/bjbms.2016.1568

INTRODUCTION

Multiple myeloma (MM) is a malignancy of B lymphocytes or plasma cells. It is a biologically complex disease characterized by excessive numbers of abnormal plasma cells in the bone marrow, and overproduction of intact monoclonal immunoglobulin of a single type [1]. It is the second most common hematologic cancer, representing 1% of all cancer diagnoses and 2% of all cancer deaths [2]. In Malaysia, more than 50% of myeloma patients are diagnosed at the late stage of the disease, and MM is more prevalent in men than women [3]. Gene expression changes, translocations, mutations, chromosomal deletions, and epigenetic changes are key factors underlying the molecular pathogenesis of MM [4-6]. Although recent advances in treatment strategies have improved survival and quality of life in patients with MM, MM is still an incurable disease. Drug resistance remains the main problem in MM patients.

Nicotinamide (NAM) phosphoribosyltransferase (NAMPT) is a key enzyme involved in nicotinamide adenine dinucleotide (NAD+) salvage pathway [7]. Overexpression of NAMPT has been found in various human malignancies including ovarian, breast, colorectal, gastric, prostate, well-differentiated thyroid and endometrial carcinomas, and MM, melanoma,
astrocytoma, and lymphoma [8]. The elevated expression of NAMPT gene promotes tumorogenesis through constant NAD resynthesis to provide adequate energy for rapidly proliferating cancer cells [9]. The inhibition of NAMPT is shown to induce cell death and reduce osteoclastogenesis in MM [10,11].

In contrast, little is known about the function of lysosomal trafficking regulator (LYST) in human cancer. The expression of LYST is shown to affect lysosomal size, granule size, and autophagy in human cells [12]. Mutation of LYST gene is associated with Chediak-Higashi syndrome (CHS), a rare autosomal recessive lysosomal disorder with hematological and immunological abnormalities [13]. Besides CHS, mutation in LYST gene is one of the key factors that cause hemophagocytic lymphohistiocytosis, a deficiency in immune system function, and life-threatening disease characterized by uncontrolled T-cell and macrophage activation [14]. In hemophagocytic lymphohistiocytosis, LYST plays an important role in controlling the terminal maturation of perforin-containing granules into secretory granules in cytotoxic T lymphocytes [15]. The role of LYST gene in oncogenesis is still unclear, and dysregulation of LYST gene has never been described in MM, nor other cancers, before.

Our previous array-based comparative genomic hybridization findings revealed gains at chromosomal 7q22.3 and 1q42.3 regions in 92% and 47% of Malaysian MM patients (n = 63), respectively [16]. More importantly, the NAMPT and LYST genes are located on 7q22.3 and 1q42.3, respectively. This led us to further study the functions of these genes in myeloma cell growth and survival by using small interfering RNA (siRNA) approach. Our findings provide a more profound understanding of the roles of NAMPT and LYST genes in the molecular pathogenesis of MM.

MATERIALS AND METHODS

Cell line

The myeloma cell line RPMI 8226 was purchased from the American Type Culture Collection (ATCC, USA). Cells were cultured in RPMI-1640 medium (ATCC) supplemented with 10% of fetal bovine serum (Lonza, Switzerland). All cells were cultured in a humidified incubator at 37°C containing 5% CO₂. The cells were passaged every 3-4 days.

siRNA transfection

Three unique siRNA duplexes for NAMPT (OriGene Cat. No.: SR306835, USA) and LYST (OriGene Cat. No.: SR300809, USA) were used to silence the respective gene in RPMI 8226 cells. The siRNAs were designated as NAMPT-a, NAMPT-b and NAMPT-c, and LYST-a, LYST-b and LYST-c. The siRNA sequences and their corresponding nucleotide binding sites are listed in Table 1. Approximately 200 nM of each siRNAs was used for transfection. Alternatively, pooled siRNAs were used (100 nM of each siRNA duplex). Pooled siRNAs were designated as NAMPT-abc and LYST-abc. Transfection of siRNAs into the RPMI 8226 myeloma cells was performed by Amaxa Nucleofection kit V (Lonza, Switzerland). Briefly, the cells were resuspended in 100 µl of nucleofector V solution mixed with 100-300 nM of siRNAs or scrambled negative control siRNAs or 2 µl of pmaxGFP at a density of 5.0 × 10⁶ cells/mL. The mixture was transferred to a cuvette and nucleofected using G-016 pulsing parameter with an Amaxa nucleofector apparatus (Lonza, Switzerland). Then, the cells were immediately transferred to pre-warmed culture medium in 12-well plates. Transfection efficiencies were determined by quantitative real time reverse transcription PCR (RT-qPCR) at 24 and 48 hours post-transfection. Each transfection was performed in two replicates and in two independent experiments.

Total RNA extraction and first strand cDNA synthesis

Total RNAs were isolated from the cells according to the manufacturer’s protocol (Qiagen miRNeasy mini kit, Germany). On-column DNA digestion was performed with

<table>
<thead>
<tr>
<th>siRNA</th>
<th>Sequences</th>
<th>Nucleotide binding sites and reference sequence accession number</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAMPT-a</td>
<td>AGAAUCUUAAGUUGGCUAACUCAA</td>
<td>2938-2962 (NM_005746.2)</td>
</tr>
<tr>
<td>NAMPT-b</td>
<td>GACAUACCUAAGAAUACUACC</td>
<td>2354-2378 (NM_005746.2)</td>
</tr>
<tr>
<td>NAMPT-c</td>
<td>AACAUGUAGUGAGAACAUAAGCAT</td>
<td>3604-3628 (NM_005746.2)</td>
</tr>
<tr>
<td>LYST-a</td>
<td>GGCACAGACGAUGAGAUAUUCA</td>
<td>1681-1705 (NM_000081.3)</td>
</tr>
<tr>
<td>LYST-b</td>
<td>GCAUGAAACCUAUAUGUAUUGTT</td>
<td>13351-13375 (NM_000081.3)</td>
</tr>
<tr>
<td>LYST-c</td>
<td>ACUGUUCAGAACAGUCAAGAGGAG</td>
<td>3182-3206 (NM_000081.3)</td>
</tr>
</tbody>
</table>

siRNA: Small interfering RNA, NAMPT: Nicotinamide phosphoribosyltransferase, LYST: Lysosomal trafficking regulator
the RNase-free DNase set to eliminate DNA contamination during RNA purification (Qiagen DNase I, Germany). Five hundred nanograms of RNAs were reverse transcribed to cDNA in a final volume of 20 µl reaction containing ×1 reverse transcriptase buffer and enzyme mix (High capacity RNA-to-cDNA kit, Applied Biosystems, USA). The reaction was incubated at 37°C for 1 hour and stopped at 95°C for 10 minutes in a thermal cycler.

Quantitative real-time PCR (qPCR)

A pre-designed TaqMan probe was used to quantitate the NAMPT (Life Technologies Cat. No.: Hs00237184, USA) and LYST (Life Technologies Cat. No.: Hs00915897_m1, USA) gene expression. Each 20 µl reaction was prepared in triplicate containing TaqMan Gene Expression Master Mix (Life Technologies, USA), a FAM dye-labeled TaqMan Gene Expression Assay (Life Technologies, USA), and 50 ng of cDNA. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an endogenous control to normalize sample input and minimize the variation between the treated and untreated samples (Life Technologies Cat. No.: Hs02758991_g1, USA). All qPCR reactions were run on an ABI 7500 Fast Real-time PCR System (Applied Biosystems, USA) in 96-well format, and the thermal cycling conditions were 95°C for 20 seconds followed by 40 cycles of 95°C for 3 seconds, and 60°C for 30 seconds. All samples were normalized to the endogenous control and fold changes were calculated through relative quantification ($2^{-ΔΔCt}$).

Enzyme-linked immunosorbent assay (ELISA)

The cells transfected with siRNAs and scrambled negative control siRNAs were collected and lysed for 30 minutes on ice at 24 and 48 hours post-transfection. After centrifugation, supernatants were collected, and the total protein concentrations were measured by using the BCA assay kit (Thermo Scientific, USA). All the proteins were diluted to 500 µg/ml before applying the NAMPT Intracellular ELISA kit (BioVision, Switzerland). ELISA reactions were performed according to the manufacturer's instructions. Standard curve was generated using two-fold serial dilutions of the cells treated with control siRNA. All the samples and standards were loaded into the plate and incubated overnight at 4°C in duplicate. Following overnight incubation, the plate was washed and read at absorbance of 450 nm in an ELISA plate reader (TECAN Sunrise, Switzerland). The NAMPT protein concentrations were estimated from the standard curve equation.

Statistical analysis

Statistical analysis was performed using Student’s t-test, and statistical significance was defined as $p < 0.05$. Data were expressed as mean ± standard deviation for two or three independent experiments.

RESULTS

Silencing of NAMPT and LYST with siRNA duplexes

In this study, pmaxGFP vectors were used to assess transfection success in RPMI 8226 myeloma cells. More than 80% of the cells expressed the green fluorescent signals at 24 hours post-transfection, indicating that the transfection was successfully procured (Figure 1A and B). The RT-qPCR results showed that the efficiency of NAMPT gene silencing was approximately 50% at 24 hours post-transfection when either NAMPT-a, NAMPT-b, or NAMPT-c siRNA was used (Figure 2A). The efficiency of gene knockdown decreased dramatically at 48 hours post-transfection for all three siRNA duplexes. When siRNA duplexes were pooled and
NAMPT-abc was used for the transfection, the gene knockdown efficiency was increased by up to >70% at 24 hours post-transfection (20% higher compared to the single siRNAs). The stability of the gene knockdown effect was maintained at 48 hours post-transfection when the pooled siRNAs were used (Figure 2A).

In addition, the RT-qPCR results showed that the efficiency of LYST gene silencing was >70% at 24 hours post-transfection when either siRNA duplex (LYST-a, LYST-b, LYST-c, or LYST-abc) was used (Figure 2B). Given that siRNA pooling is known to significantly reduce off-target effects and increase target specificity (especially in the case of NAMPT gene knockdown), pooled siRNAs, NAMPT-abc and LYST-abc, were used for the rest of the functional analysis.

siRNA-mediated silencing of NAMPT and LYST inhibited proliferation of RPMI 8226 cells

A significant decrease in the cell growth was observed in NAMPT-abc- and LYST-abc-treated cells when compared to the cells transfected with scrambled negative control siRNAs (p < 0.05) (Figures 3A and B). These findings showed that the suppression of NAMPT or LYST gene led to the inhibition of cell proliferation in RPMI 8226 cells.

NAMPT and LYST induced apoptosis in RPMI 8226 cells

To investigate the biological impact of NAMPT or LYST inhibition on the apoptosis in myeloma cells, RPMI 8226 cells were transiently transfected with NAMPT-abc or LYST-abc

---

**FIGURE 1.** Estimated transfection efficiency. (A) RPMI 8226 cells were nucleofected with pmaxGFP vectors; the expression of green fluorescent protein was monitored at 24 hours post-transfection. (B) Image of the same cells under regular microscope with the same magnification as in A part.

**FIGURE 2.** Effects of transfection with small interfering RNA (siRNA) on nicotinamide phosphoribosyl transferase (NAMPT) and lysosomal trafficking regulator (LYST) mRNA levels in RPMI 8226 cells at 24 and 48 hours post-transfection, determined by quantitative real time reverse transcriptase PCR. (A) Cells were transfected with either NAMPT-a, NAMPT-b, NAMPT-c (200 nM) or pooled siRNAs NAMPT-abc (100 nM for each siRNA). (B) Cells were transfected with either LYST-a, LYST-b, LYST-c (200 nM) or pooled siRNAs LYST-abc (100 nM for each siRNA). *p < 0.05 compared with the control.

**FIGURE 3.** Proliferation of RPMI 8226 cells following transfection with nicotinamide phosphoribosyl transferase (NAMPT)-abc or lysosomal trafficking regulator (LYST)-abc siRNA for 24, 48 and 72 hours, determined by MTT assay. (A) Cell proliferation in NAMPT-abc-treated cells, (B) Cell proliferation in LYST-abc-treated cells. *p < 0.05 compared with the control.
siRNAs and the apoptotic cell death was measured using Annexin V-FITC/PI staining. The flow cytometry analysis showed that NAMPT-abc- and LYST-abc-treated cells significantly increased the numbers of early apoptotic cells compared to the cells treated with scrambled negative control, which was 26.9% versus 55.3% in NAMPT-abc-treated cells and 26.9% versus 41.5% in LYST-abc-treated cells (p < 0.05) (Figures 4A and B). This scenario indicated that silencing of NAMPT or LYST could induce apoptosis in RPMI 8226 myeloma cells.

Decreased protein expression level after the silencing of NAMPT gene

NAMPT protein expression levels in RPMI 8226 cells treated with siRNAs and scrambled negative control were estimated using ELISA assay. The OD readings indicated that the silencing of NAMPT gene using NAMPT-abc siRNAs resulted in a dramatic reduction of the NAMPT protein levels at 24, 48 and 72 hours post-transfection (p < 0.01) (Figure 5). Moreover, the ELISA assay showed that the protein expression levels were also reduced in NAMPT-b-treated cells, although the gene knockdown efficiencies for this siRNA were only about 50% at 24 and 48 hours post-transfection (Figure 2A and 5).

DISCUSSION

MM is a genomically complex heterogeneous disease composed of several molecular subtypes with varying clinicopathological features and disease outcomes [11]. This disease remains incurable although advances in treatment have improved the overall survival rate of the patients. Drug resistance is the major problem in MM therapy, which highlights the importance of identifying new molecular targets for therapies, to combat this disease [10].

The NAD+ is a pivotal signaling molecule, which is involved in maintaining the functions of a wide variety of NAD+-dependent enzymes in the cytoplasm and nucleus. NAMPT and nicotinamide mononucleotide adenylyltransferase (NMNAT) are two key enzymes included in the NAD+ salvage pathway [17]. NAMPT catalyses the conversion of NAM to NAM mononucleotide (NMN), which is then converted to NAD+ by NMNAT [18]. In humans, normal NAMPT expression is required during early embryo development, lymphocyte differentiation, muscle cell differentiation, maturation, and senescence [19-23]. In cancerous cells, more NAD+ is needed to generate adenosine triphosphate, to supply energy for cell growth and survival [24]. Therefore, NAMPT expression is expected to be higher in cancer patients. The elevation of NAD establishes conditions for transcription regulation via
Recent studies have shown that the treatment of MM cell lines and xenograft models with FK866, a small molecule inhibitor, is able to inhibit NAMPT and induce MM cell death through autophagy mechanism. However, in these studies, the treatment of MM with FK866 did not induce cell death through apoptotic event [24,35]. The NAD⁺ intracellular shortage, triggered by FK866 treatment, could cause autophagic cell death via two possible molecular mechanisms. First, autophagy is shown to be induced by inhibiting mammalian target of rapamycin signaling, a critical negative regulator of autophagy, along with a decrease in phosphoinositide 3-kinase and protein kinase B/AKT [35]. Second, the autophagy mechanism is induced by transcriptional activation of several autophagy-related genes through the inhibition of mitogen-activated protein kinase signaling pathway and nuclear localization of transcription factor EB [35]. Although these studies showed that MM cell death was induced by autophagy rather than apoptosis, it is possible that the pharmacological restriction of NAD⁺ in MM cells triggers apoptotic signaling, which is then limited by concomitant onset of autophagy and the terminated apoptosis could then switch autophagy into MM cell death program. This explains why apoptosis cell death was not observed in the study of Cea et al. [35].

Unlike NAMPT, little is known about the function of LYST gene in human cancer. It has been shown that LYST gene is required for organizing endosomal resident proteins into late multivesicular endosomes by a mechanism that involves microtubules [36]. Recent findings have shown that LYST plays an important role in the transportation of materials into lysosomes, a place where toxic substances and bacteria are broken down and digested. Furthermore, LYST helps in maintaining the lysosomal size and regulating its movement within cells [12]. Our findings revealed that LYST gene was successfully knockdown by siRNAs in RPMI 8226 myeloma cells. For the first time, we showed that siRNA-mediated silencing of LYST inhibits proliferation and induces apoptosis in RPMI 8226 myeloma cells. The over-expression of LYST might contribute to the MM transformation and disease progression by activating cell proliferation and inhibiting apoptosis events.

Due to the budget constraint, the LYST protein expression level in the siRNA-transfected cells was not measured in the current study. Therefore, we are not certain whether LYST gene silencing has any impact on the protein translation. Since the ELISA kit for LYST protein detection is not commercially available, we aim to determine the effect of siRNA-mediated silencing of LYST on the protein expression by Western blot assay in our future research.

CONCLUSION

This study demonstrated that NAMPT and LYST genes play pivotal roles in the molecular pathogenesis of MM. This is the first report describing the possible functions of LYST in
myelomagenesis and its potential role as a therapeutic target in MM.

ACKNOWLEDGMENTS

This study was supported by research funding from the Ministry of Health, Malaysia (JPP-IMR: 12-035). The authors would like to thank the Director General of Health, Malaysia for his permission to publish the research findings and the Director of the Institute for Medical Research for her support in the publishing of this paper.

DECLARATION OF INTERESTS

The authors declare no conflict of interests.

REFERENCES


